Re: Invitation to Workshop on Pharmas Use of Grids

The OGF has produced a couple of strawman specifications for the 
incorporation of Semantic Web standard recommendations into grid. If 
you're interested in grid, you may want to take a look at the documents.

WS-DAI-RDF(S) Querying 
<http://forge.gridforum.org/sf/docman/do/downloadDocument/projects.dais-wg/docman.root.current_documents/doc14074>  
- WS-DAI RDF(S) Realization for SPARQL Query Language.  Isao Kojima & 
Said Mirza

WS-DAI-RDF(S) Ontology 
<http://forge.gridforum.org/sf/docman/do/downloadDocument/projects.dais-wg/docman.root.current_documents/doc14083> 
-  WS-DAI RDF(S) Realization for accessing RDF(S) data resources by 
means of ontological primitives. Miguel Estaban Gutierrez

Kind regards,

Susie







Eric Neumann wrote:
>
> Forwarding this to the group...
>
>
> Invitation to Workshop on Pharmas Use of Grids
>
>
> When: January 30, 2007, 2 PM
>
> Where: At Open Grid Forum 19, UNC Chapel Hill Friday Center, 100 
> Friday Center Drive
> Chapel Hill, NC 27599
> (919) 962-3000
> www.fridaycenter.unc.edu <http://www.fridaycenter.unc.edu/> 
>
> Duration: 90 minutes. There is a standards orientation presentation at 
> 8 AM that will provide a broad overview of OGF's efforts.
>
> Format: A roundtable discussion where participants raise issues and 
> have time to discuss the details and situation when such issues arise. 
> No formal presentations. Effort will be made to focus on two-three 
> priority issues and to offer enough detail to illustrate the context 
> when the issues arise.
>
>
> Purpose: To discuss how pharma firms are using Grids and the main 
> issues they have will Grids. This effort is to identify specific 
> issues that can be addressed by the Open Grid Forum's Technology 
> Standards Group and the various Working Groups of OGF. The hope is 
> that by identifying these issues, end-users can help the OGF focus on 
> end-user needs and speed work on standards that help pharma firms use 
> Grids more effectively.
>
> Agenda: To review points made at the Pharma and Grid Workshop 
> Washington meeting in September (see attached summary). To provide 
> more specificity on the issues raised, i.e., to fill in more details 
> about when the issues arise, in what context, while using what 
> applications, and in what types of processing and use of data. This 
> would place the issues squarely in an understandable context and help 
> get OGF action going.
>
>
> Invitees: The participants in the Washington review (Alex L. Bangs of 
> Entelos, John Saalwaechter of Lilly, Timothy Wagner of BMS, Jeff 
> Mathers of J&J, and Sanjoy Ray of Merck). Others in the industry will 
> also be invited. These people include Peter S. Shenkin of Schrodinger, 
> Robin deMent and Alex Roses of GSK, Stephen Perrenod of Exludus, Carol 
> Hamilton of Paragen, Todd Fuqua of Sphinx (Lilly), Max Wallace of 
> Cogent Neurogenetics, Dean F. Bushey of BayerCropScience, Mark Dibner 
> of BioAbility, Scot Huber of
> Scynexis, Blaze Stancampiano, Charles Jaffe, and Otto Ritter of 
> AstraZeneca, Abdelazize Laoui of Sanofi-Aventis, Chris Dagdigian of 
> The BioTeam, Jim Golden and John Murphy of CuraGen, Jonathan McIntyre 
> of Monsanto, Sam Yenne of Paradigm Genetics, Chris Woodward of 
> Targacept, and others.
>
>
> RSVP: Bob Cohen, Area Director, Industrial Applications, OGF. 
> bcohen@bway.net <mailto:bcohen@bway.net>  or 917-705-6524. 
>
>
>
>
>
> Eric Neumann, PhD
> co-chair, W3C Healthcare and Life Sciences,
> and Senior Director Product Strategy
> Teranode Corporation
> 411 1st Avenue South, Suite 700
> Seattle, WA 98104
> +1 (781)856-9132
> www.teranode.com
>
>
>

Received on Thursday, 18 January 2007 20:38:41 UTC